Results 71 to 80 of about 28,157 (212)

Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers

New England Journal of Medicine, 2021
Breakthrough SARS-CoV-2 Infections in Health Care Workers In a German study, 4 health care workers out of 1137 (0.35%) who had received one of the mRNA SARS-CoV-2 vaccines had mildly symptomatic Co...
Lange, Bettina, Gerigk, Marlis, Tenenbaum, Tobias   +2 more
openaire   +2 more sources

Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection

Frontiers in Immunology, 2022
Three COVID-19 vaccines have received FDA-authorization and are in use in the United States, but there is limited head-to-head data on the durability of the immune response elicited by these vaccines.
Behnam Keshavarz, Nathan E. Richards, Lisa J. Workman, Jaimin Patel, Lyndsey M. Muehling, Glenda Canderan, Deborah D. Murphy, Savannah G. Brovero, Samuel M. Ailsworth, Will H. Eschenbacher, Emily C. McGowan, Barbara J. Mann, Michael R. Nelson, Alexandra Kadl, Alexandra Kadl, Judith A. Woodfolk, Thomas A.E. Platts-Mills, Jeffrey M. Wilson   +17 more
doaj   +1 more source

Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine [PDF]

, 2022
Claudia Gandolfo, Gabriele Anichini, Marco Mugnaini, Monica Bocchia, Chiara Terrosi, Anna Sicuranza, Gianni Gori Savellini, Alessandro Gozzetti, Federico Franchi, Maria Grazia Cusi   +9 more
openalex   +1 more source

Factors Affecting Immune Reconstitution Post‐Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination

European Journal of Haematology, Volume 116, Issue 4, Page 336-349, April 2026.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot, Frederic Baleydier, Laure Pittet, Geraldine Blanchard‐Rohner   +3 more
wiley   +1 more source

Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection [PDF]

, 2021
Mina Psichοgiou, Andreas Karabinis, Garyphallia Poulakou, Anastasia Antoniadou, Αnastasia Kotanidou, Dimitrios Degiannis, Ioanna D. Pavlopoulou, Antigoni Chaidaroglou, Sotirios Roussos, Elpida Mastrogianni, Irene Eliadi, Dimitrios Basoulis, Konstantinos Petsios, Konstantinos Leontis, Eleni Kakalou, Konstantinos Protopapas, Edison Jahaj, Maria Pratikaki, Konstantinos N. Syrigos, Παγώνα Λάγιου, Helen Gogas, Sotirios Tsiodras, Gkikas Magiorkinis, Dimitrios Paraskevis, Vana Sypsa, Angelos Hatzakis   +25 more
openalex   +1 more source

Mass‐Standardised Differential Antibody Binding to a Spectrum of SARS‐CoV‐2 Variant Spike Proteins: Wuhan, Alpha, Beta, Gamma, Delta, Omicron BA.1, BA.4/5, BA.2.75 and BA.2.12.1 Variants—Antibody Immunity Endotypes

Immunology, Volume 177, Issue 4, Page 798-809, April 2026.
Fully quantitative, mass‐standardised, antibody responses to ten SARS‐CoV‐2 variants show significant variation in immunity profiles or endotypes. The incidence of the complete response to all variants is significantly improved after three vaccinations.
Philip H. James‐Pemberton, Shivali Kohli, Jordan Twynham, Aaron C. Westlake, Alex Antill, Rouslan V. Olkhov, Andrew M. Shaw   +6 more
wiley   +1 more source

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study [PDF]

, 2022
Jing Lian Suah, Masliyana Husin, Peter Seah Keng Tok, Boon Hwa Tng, Thevesh Thevananthan, Ee Vien Low, Maheshwara Rao Appannan, Faizah Muhamad Zin, Shahanizan Mohd Zin, Hazlina Yahaya, Kalaiarasu M. Peariasamy, Sheamini Sivasampu   +11 more
openalex   +1 more source

Potent and Long‐Lasting Immunogenicity Generated by LNP‐mRNA gE Antigen Against Varicella Zoster Virus via an AI‐Assisted Pipeline

Advanced Science, Volume 13, Issue 14, 9 March 2026.
This study designs a novel mRNA‐LNP vaccine targeting VZV glycoprotein E (gE) for herpes zoster via an AI‐assisted pipeline. Validated in mice and rhesus macaques, the mRNA‐LNP vaccine shows strong humoral and cellular immune responses, with CD4+ T‐cell responses more effective and durable than Shingrix, offering a promising prophylactic option ...
Kai Dong, Fang Liu, Dawei Wang, Yanfen Li, Man Zhang, Yuting Zhou, Gengshen Song   +6 more
wiley   +1 more source

Boosting BNT162b2 vaccine efficacy in CLL [PDF]

Blood, 2022
Bhat, Seema A., Woyach, Jennifer A.
openaire   +2 more sources

Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain

Scientific Reports, 2022
Scarce data have been reported about cellular immunity and longevity for different COVID-19 vaccination schedules. We carried out a prospective study enrolling 709 healthcare workers receiving two doses of mRNA-1273, BNT162b2, ChAdOx1, ChAdOx1/BNT162b2 ...
Leire Fernández-Ciriza, Álvaro González, José Luis del Pozo, Alejandro Fernández-Montero, Francisco Carmona-Torre, Silvia Carlos, María del Mar Sarasa, Gabriel Reina   +7 more
doaj   +1 more source